June 21, 2019
Sanofi, Regeneron’s monotherapy reduces loss of asthma control, improves lung function vs placebo
Sanofi and Regeneron Pharmaceuticals said Friday a Phase 2 proof-of-concept trial evaluating the investigational IL-33 antibody REGN3500 (SAR440340) met the primary endpoint of improvement in loss of asthma control when comparing REGN3500 monotherapy to placebo.